The HER-2/Neu oncogene has been implicated in human and mouse breast cancer. Indeed, transgenic MMTV-neu mice expressing this oncogene from the mammary tumor virus long terminal repeat develop spontaneous mammary tumors and die within 1 year of life. We have expressed the class II transactivator (CIITA) and/or the costimulatory molecule CD80 (B7.1) in a mammary carcinoma cell line (MCNeuA) derived from these mice. Class II transactivator directs the expression of MHC class II and the machinery for antigen processing and presentation by this pathway. When injected into MMTV-neu mice, tumor cells expressing CD80 or CD80 and CIITA, were rejected completely. In addition, following the rejection of dual expressing cells, 75% of the mice were protected against the development of subsequent spontaneous tumors. Cells expressing only CD80 or CIITA were not as effective as antitumor vaccines in preventing the development of spontaneous tumors. Thus, converting cancer cells into antigen presenting cells could represent an effective immunotherapy for breast cancer.
Introduction
One of the major goals of tumor immunotherapy is the induction of tumor-specific immune responses that recognize and eradicate neoplastic cells. Insights into the mechanisms of T-cell activation have provided the basis for developing such new approaches. Both antigendependent and -independent interactions are necessary for the generation of specific effector T cells and for the establishment of T-cell memory. Activation of T cells by antigen presenting cells (APCs) requires two signals. The first signal is provided by the recognition of antigenic peptides presented by major histocompatibility (MHC) class I or class II molecules. A second costimulatory signal is provided by the ligation of CD28 on the surface of T cells by a B7 family member (B7.1 or CD80 and/or B7.2 or CD86) on these APCs. [1] [2] [3] Importantly, in some cases, T cells that have encountered antigen in the absence of a costimulatory signal undergo a state of unresponsiveness or anergy that cannot be overcome easily by subsequent costimulation. 4 A common defect in the recognition and eradication of tumor cells by T lymphocytes is the lack of appropriate antigen processing and presentation (APP) and/or the absence of costimulation by the tumor cells themselves. As the expression of CD80 is mostly limited to professional APCs, the weak immunogenicity of tumor cells could reflect the lack of appropriate costimulation of naı¨ve T cells. Indeed, tumor cells engineered to express costimulatory molecules can induce antitumor responses in several animal models of cancer. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] The coexpression of cytokine molecules with costimulatory molecules has also been shown to induce tumor immunity. [16] [17] [18] [19] [20] However, in most cases, the therapeutic efficacy of this strategy is limited, possibly due to lack of T-helper cells, whose activation depends on the expression of MHC class II. 21, 22 One limitation of this approach is the suboptimal APP by MHC class I on many tumor cells, such that the CD80-or CD86-transduced cells deliver only a costimulatory signal to T cells.
Although several attempts have been made to restore the expression of MHC determinants on tumor cells, the full restoration of APP has been more difficult, especially since it requires additional accessory molecules. The identification of the class II transactivator (CIITA), which is the master coactivator for the transcription of genes required for APP, offered new insights and possibilities for cancer immunotherapy. 23, 24 Class II transactivator not only induces the expression of the polymorphic structural a-and b-chains of MHC class II molecules but also induces monomorphic DOA and DOB, as well as the DMA, DMB, and invariant chain (Ii) genes. In some cells, CIITA can also increase the expression of MHC class I genes. [25] [26] [27] Thus, engineering tumor cells to express CIITA can reconstitute APP by both the MHC class I and class II compartments, and with the addition of costimulatory molecules may transform them into APCs.
Despite this promise, results of such manipulations of tumor cells have been variable. In some tumors, the expression of CIITA and CD86 paradoxically increased the growth of the tumor. 28 In others, the absence of Ii led to a greater immunogenicity of tumors, presumably because of better loading of self-peptides onto the unprotected structural heterodimers during their biosynthesis. 29 Finally, in other studies, CIITA had therapeutic effects even in the absence of costimulation. 30 Variable levels of expression of transduced genes and/or the extinction of MHC class II on tumor cells might explain some of these findings. Alternatively, some of these solid tumors might express endogenous costimulatory molecules. In this study, we examined whether high levels of expression of MHC class II and CD80 molecules could create an effective antitumor vaccine against the development of mouse mammary tumors. We expressed these molecules in MCNeuA cells, which were derived from MMTV-neu mice. 31 We describe the impact of expressing CIITA and CD80, alone or in combination, on the ability of these cells to form tumors in MMTV-neu mice as well as their effects on the development of spontaneous mammary tumors in these mice.
Materials and methods

Retroviral constructions
cDNAs encoding the N-terminal Flag epitope-tagged human CIITA (hCIITA) and mouse B7.1 (mCD80) proteins were subcloned into the EcoR1 site of the pWZLblast2 bicistronic retrovirus, which also encodes resistance to the antibiotic blasticidin. Recombinant amphotropic retroviruses were generated by transient transfection of Phoenix A packaging cells (PA317), as described previously. 32, 33 Transgenic mice and mammary carcinoma cell line The transgenic mice used in this study, FVB/N-TgN (MMTV-neu) N202 (denoted MMTV-neu), carries the wild-type rat neu transgene under the control of the mouse mammary tumor virus (MMTV) long terminal repeat (LTR). 34 Female MMTV-neu mice develop mammary lesions that are similar to human breast cancer. The MCNeuA mammary carcinoma cell line was established from a tumor that arose in a female MMTV-neu mouse. 31 This cell line forms tumors when transplanted into syngeneic MMTV-neu mice.
Cell culture and retroviral infection of cells
MCNeuA and PA317 cell lines were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% (v/v) heat-inactivated fetal calf serum (FCS), 100 mM L-glutamine and 50 mg each penicillin and streptomycin per ml. All cells were grown in an atmosphere of 5% CO2 at 371C. PA317 cells were plated 12 h before transfection in 100 mm tissue culture dishes. Monolayers of PA317 cells were transfected with 10 mg of pWZLblast2 (M cells), pWZLblast2:hCIITA (MC cells), pWZLblast2:mCD80 (MB cells) retroviral plasmid vectors in OptiMEM media for 5 h using Lipofectamine (Life Technologies, Grand Island, NY). Media were changed 24 h post-transfection (no antibiotics), and cells were allowed to grow for an additional 48 h. Twenty-four and 48 h supernatants were collected and cellular debris was removed by filtration. Monolayers of MCNeuA cells in mid-log growth phase were infected by the addition of 50% fresh viral supernatant and 8 mg/ml polybrene (Sigma, St Louis, MO) for 12 h. The infection was repeated with supernatants collected at 48 h. Media were changed and cells were allowed to grow for an additional 48 h before selection in 24-well dishes. Cells were selected in DMEM with 10% FCS containing blasticidin (25 mg/ ml). A pooled population of cells expressing CIITA or CD80 was trypsinized, expanded and subsequently cloned by limiting dilution. To express both CIITA and CD80 (MBC cells), CIITA selected clones cells were subsequently infected with the CD80 retrovirus. Double expressors were sorted by flow cytometry and single clones were isolated subsequently by limiting dilution.
Growing tumors were also removed from the MMTVneu mice, washed in phosphate-buffered saline (PBS) at 41C, cut into small pieces (2-4 mm), and incubated with of mixture of trypsin (0.25%) and collagenase in DMEM serum-free media at 371C for 3 h. The reaction was stopped by the addition of 10% FCS and separated cells were filtered through a fine mesh cloth. The cell suspension was then washed in PBS, plated in the complete DMEM medium with serum and allowed to grow for 24 h. Cells were analyzed as above.
Protein extracts, immunoprecipitations and Western blotting Cells were lysed in lysis buffer containing 20 mM Tris, 137 mM NaCl, 5 mM ethylenediamine-N,N,N 0 ,N 0 -tetraacetic acid and 0.5% (w/v) NP-40 and a cocktail of protease inhibitors. 35 The amount of protein was quantified with the BCA assay kit (Pierce Biotechnology, Inc., Rockford, IL). Equivalent amounts of proteins were precleared with protein A-conjugated Sepharose beads, and were subjected to immunoprecipitation by using anti-Flag M2 monoclonal antibody (mAb) (Sigma-Aldrich, St. Louis, MO). Immunoprecipitated complexes were resolved by sodium dodecyl sulfate-polyacrylamide gels (7.5% PAGE) and analyzed by Western blotting with the antiFlag M2 mAb. After washing under stringent conditions, immune complexes were revealed by using the horseradish peroxidase-conjugated anti-mouse IgG antibody (Amersham, Biosciences, Piscataway, NJ) and visualized by Challenge with mammary tumor cells expressing MHC class II and CD80 N Jabrane-Ferrat et al using an enhanced chemiluminescence, ECL-Plus, detection kit (NEN Life Science Products, Boston, MA).
Flow cytometry and immunohistochemistry
The mAbs used for these studies were: anti-CD80 (PharMingen, San Diego, CA), anti-MHC class II (antiIEb/IAb, which reacts with d, b, p, q, u and j haplotypes) (provided by Dr R Accolla, Verona, Italy), and antic-Neu (Ab-4, Oncogene Sciences, Cambridge, MA). Secondary Abs used were goat anti-mouse IgG-conjugated to either fluorescein isothiocyanate or phycoerythrin. Single-cell suspensions or monolayer cells grown on tissue culture chamber slides were washed in PBS containing 1% mouse serum, were stained with primary and secondary Ab, and then analyzed. Flow cytometry was performed on a fluorescence-activated cell sorting calibur (Becton Dickinson Immunocytometry Systems, San Jose, CA). Dead cells were excluded by their uptake and staining with propidium iodide. Cells attached to tissue culture slides were analyzed by using fluorescence microscopy (Nikon, Japan).
Tumorigenicity of cell lines
Cells at 50-80% confluency were harvested by trypsinization, washed, and resuspended at 2.5 Â 10 7 cells/ml in PBS. Two hundred microliters (5 Â 10 6 cells) were injected subcutaneously (s.c.) into the hindleg of 6-to 8-week-old female MMTV-neu mice. Mice were then monitored for tumor growth every other day starting at one week postinjection. Tumor measurements (length and width) were recorded by using a caliper. Tumor volume was calculated as (length Â width2)/2.
Lymphocyte purification and growth Single-cell suspensions were prepared from harvested spleens of 8-to 10-week-old MMTV-neu female mice using a 40 mM nylon cell strainer (Becton Dickinson). After lysis of red blood cells using ACK lysis solution (Biofluids, Rockville, MD), splenocytes were washed in PBS, layered onto Ficoll-Paque solution (Pharmacia Biotech, Piscataway, NJ) and were centrifuged for 20 min at 2000 r.p.m. at 41C. Live cells were washed and nonadherent mononuclear leukocytes were collected after depletion of adherent cells by incubation for 3 h at 371C in tissue culture flasks. The enrichment of each subset of T cells was assessed by flow cytometry. 36 MCNeuA-derived cells were plated to 80-90% confluency 24 h before the assay in 96-well flat-bottom plates (Costar, Gaithersburg, MD), and were irradiated with 3000 Rads 3-4 h before use as APC. Purified lymphocytes were treated for 3 h with 0.5 mM phorbol myristate acetate plus 0.1 mM Ionomycin and then were plated at 5 Â 10 4 cells/well onto a monolayer of irradiated mammary cells in a final volume of 200 ml/well. Media were changed every 2-3 days for a total of 6 days. Cultures were pulsed with 1 mCi of [
3 H]thymidine and were harvested 16 h later onto glass filters by using a 96-well plate harvester. Incorporated radioactivity was measured by using a liquid scintillation counter. Results are presented as mean thymidine uptake 7s.e.m.
Statistical analyses
Comparisons of tumor sizes were performed by using the Student's t-test. Tumor incidence curves were analyzed by Wilcoxon's two-sample test.
Results
Expression of CD80 and/or CIITA in MCNeuA cells
To stably express high amounts of CD80 and MHC class II molecules in MCNeuA cells, we constructed replication-defective retroviral expression plasmids, which encoded the cDNAs of interest and the blasticidin resistance gene. The mouse CD80 and human Flag epitope-tagged CIITA open reading frames were inserted in the EcoR1 site of the pWZLblast2 retroviral vector. In pWZLblast2, the genes of interest, followed by the internal ribosomal entry site (IRES) from the encephalomyocarditis virus and the blasticidin resistance gene, are transcribed from the MLV LTR. 37, 38 Amphotropic retroviruses were produced and used to infect MCNeuA cells. Resistant colonies were drug-selected, expanded, and isolated by limiting dilution cloning. With each retroviral transduction, at least three independent clones were assayed for the expression of the appropriate genes. Cells expressing the highest amounts of the transduced genes were characterized further and used throughout the study. Figure 1A , panels c and g) whereas MC cells did not express CD80 ( Figure 1A , panel e). As MC and MBC cells contained CIITA ( Figure 1B, lanes 3 and 4) , they expressed high amounts of MHC class II on their surface ( Figure 1C , white peak, MBC panel). Although only MBC cells are presented in Figure 1C , similar results were obtained with the MC cells. Of note, the amounts of MHC class II expressed on these transfectants, as measured by immunofluorescence, were three logs over the background fluorescence, which is similar to amounts of MHC class II found on activated B cells (data not presented). We conclude that MCNeuA cells were transduced efficiently with the retroviral vectors and expressed high levels of the introduced genes.
MB, MC and MBC cells stimulate lymphocyte proliferation in vitro
To examine functional consequences of expressing CD80 and/or CIITA in MCNeuA cells, we performed proliferation assays with nonadherent syngeneic mouse splenocytes, cocultured with M, MB, MC or MBC cells in vitro. As shown in Figure 2 , MB (white squares), MC (white diamonds) and MBC (black stars) cells were able to increase the proliferation of lymphocytes as measured by (Figure 2, white circles) . We conclude that T cells recognize these new antigens on MCNeuA cells and that two activation signals have the greatest effect.
Suppressed growth of MC, MB and MBC cells in MMTV-neu mice
To determine whether the expression of CD80 and/or CIITA in MCNeuA cells effects tumor growth in MMTVneu mice, groups (n ¼ 8-14) of 6-to 8-week-old MMTVneu female mice were inoculated s.c. with 1 Â 10 6 modified tumor cells and monitored for a period of 40 days. Mice in the control group were inoculated with M cells. These M cells are highly malignant and tumors arose 12 days after inoculation. Indeed, all these mice had to be killed by day 40 (Figure 3, white circles) . In contrast, expression of CIITA in MC cells slowed tumor growth (Figure 3 , white diamonds). Although seven out of eight mice in this group developed tumors, these tumors were significantly smaller compared to those in the MMTV-neu mice that received M cells (Figure 3 , white diamonds). The expression of either CD80 alone or CD80 and CIITA in MCNeuA cells resulted in complete inhibition of tumor growth in MMTV-neu mice that received MB and MBC cells (Figure 3 , white squares and black stars). We repeated these experiments with two independently derived MB, MC and MBC clones and obtained similar results (data not presented). We conclude that expression of the costimulatory CD80 molecule alone or together with MHC class II prevents the growth of mammary tumors in MMTV-neu mice. These findings correlated with the in vitro proliferative responses presented in Figure 2 .
To determine if MC cells continued to express MHC class II after prolonged growth in MMTV-neu mice, these tumors were explanted 27 days after the initial inoculation. Cell suspensions prepared from the tumors were analyzed for MHC class II expression by flow cytometry as described in Figure 1c . Representative data of explanted tumor cells are presented in Figure 4 . As shown, a significant proportion of MC tumor cells explanted at day 27 have lost the expression of MHC class II. This finding most likely reflects not only the presence of normal cells but also the ability of tumor cells Challenge with mammary tumor cells expressing MHC class II and CD80 N Jabrane-Ferrat et al bearing low levels of MHC class II to survive better in MMTV-neu mice. As MC and MBC cells did not grow in MMTV-neu mice, the evolution of CD80 could not be followed in parallel. Thus, although the presence of MHC class II delayed the progression of MC tumors (Figure 3) , the subsequent loss of MHC class II molecules may explain the eventual outgrowth of these tumors.
Immunizations with MB and MBC cells reduces the incidence of spontaneous mammary tumors in MMTV-neu mice To determine the effects of expressing CD80, or CD80 plus CIITA, in MCNeuA cells on the development of spontaneous mammary tumors, MMTV-neu mice were given a single injection of MB or MBC cells at 6 weeks of age and followed over time for tumor growth. The injected tumor cells were rejected completely. In addition, only half of the mice that were inoculated with MB cells ( 
Challenge with mammary tumor cells expressing MHC class II and CD80
N Jabrane-Ferrat et al cells proliferated (Figure 4 ) and these mice had to be killed early because of transplanted rather than spontaneous tumors. Histologic analyses were performed on mammary tissues derived from 35 week-old mice that were inoculated with MBC cells. As presented in Figure 6 , wild-type MMTV-neu mice developed massive mammary tumors composed of poorly differentiated, densely packed tumor cells (left panels, low and high power views). In contrast, mice inoculated with MBC cells did not develop tumors and had histologically normal mammary glands ( Figure 6 , right panels, low and high power views). The only exception was the appearance of dense mononuclear infiltrates near the ducts in the mice that received the MBC cells 9 months earlier ( Figure 6, right panel, m) . It is likely that these infiltrates represent antitumor immune responses in these manipulated MMTV-neu mice. These histological findings suggest that the absence of mammary tumors is due to beneficial immune responses in the immunized MMTV-neu mice.
Discussion
In this report, we demonstrated that expression of CD80 or CD80 and CIITA molecules in mouse mammary tumor cells abrogates their tumorigenicity. Furthermore, these cells when administered as a single injection to 6-weekold MMTV-neu transgenic mice, conferred significant Challenge with mammary tumor cells expressing MHC class II and CD80 N Jabrane-Ferrat et al protection from the subsequent development of spontaneous mammary tumors. These findings suggest that mammary tumor cells can become efficient APCs that immunize against the development and growth of breast cancer. As such, they may serve as an effective antitumor vaccine.
Although expression of CIITA alone delayed tumor growth, it did not completely inhibit it (as compared to CD80 or CD80 plus CIITA). This finding could be due to the need for the coexpression of a costimulatory molecule such as CD80. Alternatively, the lack of complete tumor inhibition may have been due to a loss of MHC class II expression over time in vivo (see Figure 4) . Loss of MHC class II expression may also explain the observation that mice immunized with CD80 plus CIITA expressing tumor cells were not protected completely against spontaneous tumor growth ( Figure 5 ). Thus, repeated immunizations with cells expressing CIITA and CD80 should circumvent this problem.
In vivo animal immunotherapy models using tumor cells transfected with CIITA have been reported for a mouse sarcoma, SaI, 29 lung carcinoma, Line 1, 28 and mammary adenocarcinoma, TS/A. 30 As in our study, transfection of CIITA resulted in the expression of MHC class II molecules in each of these models. However, effects of CIITA expression on tumor growth in vivo varied. For example, SaI tumor cells expressing CIITA or only structural MHC class II determinants were not or were rejected when injected into mice, respectively. In contrast to these two studies, the expression of CIITA in TS/A mammary carcinoma cells significantly reduced their tumorigenicity and mice that rejected TS/A-CIITA cells were resistant to a subsequent challenge with parental TS/A tumor cells.
The differences in results between these four studies may be due to differences in the types of tumors used. TS/A and MCNeuA are mammary carcinomas as compared to the SaI sarcoma and the Line 1 lung carcinoma. MCNeuA cells differ from TS/A in that they were derived from a spontaneous mammary tumor in a Neu transgenic mouse. As such, the MCNeuA cell line overexpresses the Neu receptor tyrosine kinase (RTK). Interestingly, the Neu RTK activates the mitogen activated kinase signaling cascade, which in turn can increase the transcriptional activity of CIITA. 39, 40 Variable levels of expression of the transduced genes and/or the extinction of MHC class II on tumor cells might also explain some of the differences in results between these studies.
The findings from this study and others suggest that converting tumor cells into APCs, tumor-APCs, is a potentially useful immunotherapeutic strategy. In tumorAPCs, the presentation of endogenous tumor antigens is expected to improve, especially since the APP machinery is turned on maximally even when exogenous antigens, such as bacteria, are not encountered. Some of these endogenous antigens might also enter tumor-APCs by endocytosis or pinocytosis of exosomes and debris from apoptotic cells. This MHC class II APP of exogenously delivered antigens would not suffer from the inhibition of early peptide loading provided by the Ii. Indeed, differential formation of exosomes and/or levels of apoptosis of tumor cells could well explain differences between various studies with tumor-APCs. Importantly, we also used live cells that provided continuous antigenic stimulation. Additional considerations include the presence or absence of appropriate proteases that cleave these proteins, antigens that can be recognized by the immune system, and the abundance of regulatory T cells (Tregs), which might blunt as vigorous an immune response as would be required. Some of these could be overcome by the addition of specific cytokines, such as IFNg and/or GM-CSF, blocking effects of TGFb or IL10, as well as the addition of optimized antigens and/or antigenic peptides to these tumor-APCs. Indeed, with breast cancer, most of these other approaches have been tried in animal models and in patients, some with highly encouraging results. [41] [42] [43] [44] [45] [46] [47] [48] [49] Although these results are promising, the next step is to identify a clinically feasible method to deliver this type of immunotherapy. Although live cells were used in our study, the use of inactivated tumor-APCs, transduced ex vivo with CIITA, costimulatory molecules (CD80 or CD86), and/or cytokines or chemokines, would be a more feasible approach and will be evaluated in our preclinical model. Alternatively, viral or nonviral systems could be used to deliver CIITA and CD80 expression constructs directly to tumor cells in vivo. Since the expression of these genes should lead to an immune response against the tumor, the delivery system would not have to be 100% efficient. Transduction of only a fraction of the tumor may be sufficient to elicit an immune attack against the untransfected cells as well.
